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ABSTRACT: A series of imidazol-1-ylethylindazole sodium
channel ligands were developed and optimized for sodium
channel inhibition and in vitro neuroprotective activity. The
molecules exhibited displacement of a radiolabeled sodium
channel ligand and selectivity for blockade of the inactivated
state of cloned neuronal Nav channels. Metabolically stable
analogue 6 was able to protect retinal ganglion cells during
optic neuritis in a mouse model of multiple sclerosis.
■ INTRODUCTION
Voltage-gated sodium (Nav) channels are the fundamental
generators of electrical impulses (action potentials) in the
membranes of excitable cells. A number of clinically used drugs
exert their therapeutic eﬀects through Nav. These drugs are
primarily used in the treatment of central nervous system
(CNS) disorders, such as epilepsy and neuropathic pain, but are
increasingly being scrutinized as potential treatments for
neurodegenerative conditions occurring acutely, such as in
ischemic stroke, or chronically, as in multiple sclerosis (MS).1
Phenytoin 1 was one of the ﬁrst antiepileptics developed
(Figure 1). It exerts a voltage-dependent and frequency-
dependent block of Na+ currents. This selectivity is suggested
to be the reason for its lack of signiﬁcant cognitive side eﬀects.2
Other ﬁrst-generation antiepileptics that act on Nav channels
include lamotrigine 2,3 and carbamazepine 34 (Figure 1).
Recently, lacosamide 4 was approved for use in partial-onset
seizures and neuropathic pain. Lacosamide is proposed to act
via an unique mechanism of state-dependent blockade of Nav
channels: stabilizing channels in a slow inactivated state without
eﬀects on fast inactivation.5
Nine Nav channel isoforms have been identiﬁed, of which,
Nav1.1, 1.2, 1.3, and 1.6 are predominately found within the
CNS, whereas Nav1.7, 1.8, and 1.9 are located in the peripheral
nervous system. Nav1.4 is found within skeletal muscle, and
Nav1.5 is found in the heart. The Nav isoforms are also
expressed outside their primary tissues.6 Recently, the ﬁrst X-
ray crystal structure of a voltage-gated sodium channel was
solved: initially in the closed state and subsequently in two
presumed inactivated states.7,8 Under normal physiological
conditions, the channels interconvert between diﬀerent func-
tional states: the resting state in which the channel pore is
closed, an open state in which the channel pore is open and
permeable to Na+, and one or more inactivation states where
the pore is open but blocked.9
Recent studies have highlighted the importance of Nav1.3,
1.7, 1.8, and 1.9 in various pain syndromes.10−12 Notably,
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Figure 1. Compounds with sodium channel modulatory activity.
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genetically inherited pain disorders have been associated with
mutation of these Nav encoding genes.
13 Clinically, carbama-
zepine, lamotrigine, and phenytoin are all used to treat
neuropathic pain.14 The Merck, Pﬁzer, AstraZeneca, and
GlaxoSmithKline pharmaceutical groups have all independently
reported their own series of 1.3-, 1.7-, and 1.9-selective sodium
channel modulators for use in neuropathic pain,15 exempliﬁed
here by the benzazepinone compounds from Merck Pharma-
ceuticals, such as 5 (Figure 1).16,17
Sodium channel blockers can exhibit signiﬁcant neuro-
protective eﬀects.18 Inﬂux of sodium from the extracellular
space during reperfusion plays a major role in excitotoxic
neuronal death after cerebral ischemia.19 Block of Nav channels
can attenuate the primary events that occur in an ischemic
attack, most likely by blocking Na+ permeability, resulting in
reduced ATP depletion and reduced ischemic-induced release
of glutamate.20 A number of drugs, including lamotrigine, BW-
1003C87, the local anesthetic lidocaine, and sipatrigine, have all
shown neuroprotective eﬀects in animal models of stroke.21−24
However, as of yet, these results have failed to translate into
beneﬁcial eﬀects in clinical trials.25,26 Thus, there is a need for
drugs with a better clinical eﬃcacy and therapeutic index.
Treatment of stroke is limited by the fact that administration of
treatment in humans only occurs sometime after the onset of
the neurodegenerative insult. In contrast, for slowly evolving
neurodegenerative conditions, it is possible to treat during or
even before individual neurodegenerative episodes occur.
Carbamazepine (3) is commonly used to alleviate the
symptoms of MS, such as spasms, nerve pain, and trigeminal
neuralgia, and lamotrigine has been trialled in neuroprotec-
tion.27 Research into the potential neuroprotective eﬀects of
these compounds is gaining increasing momentum because of a
better understanding of the role of Nav channels in nerve
damage.28
To understand the role of individual Nav channel isoforms in
neuroprotection, we need to consider their distribution.
Although most of the sodium channel variants are expressed
at diﬀerent levels in the CNS, Nav1.6 expression is widespread
29
but is more abundant in nerves of the retina, cerebellum, and
cortex tissue.30 In a mature, myelinated axon, Nav1.6 tends to
cluster and is the predominant isoform at the nodes of
Ranvier.31 A signiﬁcant increase in Nav1.6 density can be seen
subsequent to nerve ﬁber injury in traumatic brain injury and
multiple sclerosis.32−34 Nav1.6 has also been implicated in
secondary degeneration of neuronal cells. Mechanical, ischemic,
and inﬂammatory insult can, over time, contribute to this
degeneration. Shear and stretch forces, despite not destroying
the cells or severing the axons can, nonetheless, produce
secondary degeneration in brain tissues.35 Rapid tetrodotoxin-
sensitive calcium overload occurs in stretch-traumatized axons,
which suggests that in neuropathologic conditions structural
degradation of the axolemmal bilayer can foster a chronically
left-shifted Nav channel operation. This points to leaky Nav
channels playing an important role in determining neuronal cell
survival.36 Other Nav channel isoforms, namely, Nav1.1
37 and
Nav1.3, have also been implicated in traumatic brain injury
models.38 Overall, there is no clear understanding of the
speciﬁc contributions of each isoform to the neuroprotective
eﬀect; we anticipate that investigations of the action of well-
characterized compounds will aid in this regard. Previous work
by this group designed a class of voltage-dependent sodium
channel modulators based on the indazolyloxadiazolyl scaf-
fold.39 Further development of analogues around this scaﬀold
has now identiﬁed a series of imidazolylethylindazoles with
good neuroprotective eﬀects. Following assessment of sodium
channel isoform selectivity and functional activity, a candidate
molecule, CFM6104, 6 (Figure 1), was tested in an in vivo
optic neuritis (inﬂammation of the optic nerve) mouse model
Scheme 1a
a(a) R1-bromide/chloride, Cs2CO3, DMF; (b) TFA, TIPS, H2O, (c) ArCOOH, 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluroniumhexa-
ﬂuorophosphate (HATU); (d) ArSO2Cl, Na2CO3; (e) R1-alcohol, tributylphosphine, TMAD, PhMe.
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of MS and found to prevent the consequent loss of retinal
nerve cells.
■ RESULTS
Design. In our previous investigations, we demonstrated
that aminomethyloxadiazolylindazoles had good neuroprotec-
tive activity. If the amino group was protected as a Boc group,
then the activity was generally lost. However, exploration of
alternative groups to the indazole N1/N2 benzyl revealed a Boc-
protected intermediate (vide infra) with surprising neuro-
protective activity. This molecule exhibited a diﬀerent SAR
proﬁle to the previous series with lower cytochrome P450
inhibition. We therefore carried out a detailed investigation of
the neuroprotective activities of this series. Key objectives were
to maintain the neuroprotective activity and to improve the
metabolic stability to allow evaluation in vivo.
Chemistry. The synthesis of 3-[3-tert-butoxycarbonylami-
nomethyl-1,2,4-oxadiazol-5-yl]indazole 7 (Scheme 1) has been
previously described.39 This compound was utilized as a key
synthetic intermediate for the production of a further series of
compounds. The stereoselective synthesis of alkyl N1- and N2-
heteroaromatic-substituted compounds (Scheme 1) was carried
out using a cesium- or potassium carbonate-mediated alkylation
of an alkyl halide-functionalized heteroaromatic compound
(N1), 8, or a Mitsunobu reaction with an alcohol-functionalized
heteroaromatic compound (N2), 9. Boc removal was performed
using triﬂuoroacetic acid, triisopropylsilane, and water to yield
the free amines 10 and 11. These amines were then derivatized
to provide the N1 12 and N2 13 analogues shown. The
benzamides were formed via a coupling reaction between the
free amine and R-substituted benzoic acid in the presence of
DMF, HATU, and DIPEA at room temperature. This reaction
occurred at various eﬃciencies (9−75%) across the range of
substituted oxadiazolylindazoles and substituted benzoic acids.
The sulfonamide analogues were formed by reaction of the free
amine with R-substituted benzene sulfonyl chloride in the
presence of sodium carbonate at room temperature with
reaction eﬃciencies of 24−39%.
Biological Assays. Activity against sodium channels was
assessed using a radioligand binding assay using [3H]sipatrigine
as the ligand39 and by patch-clamp electrophysiology on cloned
human channels. The in vitro neuroprotection assay was an
adaptation of an original study by Fowler and Li.40 In this
system, rat hippocampal slices are subjected to oxygen-glucose
deprivation, and the subsequent progression to cell death is
monitored by determining their ATP levels. This paradigm is
highly sensitive to blockade of sodium channels and
tetrodotoxin. The compounds were also tested for metabolic
stability in rat liver microsomes. Nav channel isoform activity
was determined using an automated patch-clamp system against
hNav1.1−hNav1.8/β3 expressing cells. T-cell immunosuppres-
sive activity was assessed using a simple contact hypersensitivity
model that detects T-cell proliferation to oxazolone in
lymphnodes.41−43 In vivo neuroprotection was evaluated in
an optic neuritis model44 using double-transgenic mice
expressing both a Thy1-promoter-driven cyan ﬂuorescent
protein restricted to retinal ganglion cells and a myelin
oligodendrocyte glycoprotein T-cell receptor (TCR).44 Follow-
ing injection of Bordetella pertussis toxin, the mice develop
subneurological experimental autoimmune encephalomyelitis
(EAE) and optic neuritis in the optic nerve, which then leads to
retinal ganglion cell loss secondary to axon damage.
Activity against Sodium Channels and Neuroprotection.
Initial testing with N1- and N2-functionalized tert-butyl
carbamate-protected analogues showed encouraging results in
the [3H]sipatrigine binding and neuroprotection assays (Table
1). Lamotrigine, sipatrigine, and tetrodotoxin were included as
reference molecules. Benzyl-functionalized molecules 14 and
15, reported in previous work, are shown for comparison.39 A
Table 1. Sodium Channel Modulatory and Neuroprotective Activity of Boc-Protected Oxadiazolyindazole Analogues
compound R (isomer) [3H]sipatrigine binding, IC50 (μM) neuroprotection at 50 μM (%)
lamotrigine 1.8 ± 0.2a 33b
tetrodotoxin 100c
sipatrigine 0.04 ± 0.001a 93d
14 CH2-Ph (N1) 8.3
e 19e
15 CH2-Ph (N2) 5.5
e 25e
16 CH2CH2-2-imidazole (N1) 7.4 ± 1.1 56 ± 5.6 (4)
17 CH2CH2-2-imidazole (N2) 15.5 ± 9.2 35 ± 5.3 (3)
18 2-py (N1) 74 ± 20.4 18 ± 7.1 (4)
19 CH2-2-py (N2) 23 ± 5.9 42 ± 3.8 (4)
20 CH2CH2-2-thiophene (N2) 166 ± 49 1 ± 13.4 (4)
21 CH2-4-(5-CH3)-isoxazole (N1) 339 ± 121 39 ± 7.8 (4)
22 CH2-C6H4-N-pyrazole (N1) 617 ± 160 20 ± 16.4 (3)
23 CH2-3,4-benzodioxole (N1) 6 ± 1.0 −3 ± 6.2 (4)
aValues reported in literature.39 bTested at 30 μM. Results are normalized to the eﬀect of TTX and are based on the mean of at least three
experiments. cTTX tested at 1 μM. dTested at 3 μM. eReported previously.39
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combination of reasonable potency (20 μM) and >30%
neuroprotection identiﬁes active compounds.
Replacement of the benzyl group with substituted and
nonsubstituted heteroaromatic groups showed a general
decrease in the ability of the compounds to displace the
radioactive ligand, with the notable exceptions of the
ethylimidazole analogues 16 and 17 (Table 1). Other side
chains with weakly basic pyridyl moieties, 18 and 19,
demonstrated moderate binding and neuroprotective activity,
whereas nonbasic heterocycles 20 and 21 or bulkier groups 22
and 23 displayed weak binding or low neuroprotection.
In the previous series, a free amine group led to a general
increase in the neuroprotection by the benzylindazole
analogues (e.g., compounds 24 and 25; Table 2). That trend
was not observed here. The modest neuroprotection observed
for the imidazole and pyridine analogues was removed with free
amines such as 26 and 27. This was also the case for the
pyridyl−free amines 28 and 29. The neutral side chains
Table 2. Sodium Channel Modulatory and Neuroprotective Activity of Oxadiazolylindazole Analogues
compound R (isomer) [3H]sipatrigine binding, IC50 (μM) neuroprotection at 50 μM (%)
lamotrigine 1.8 ± 0.2a 33b
tetrodotoxin 100c
sipatrigine 0.04 ± 0.001a 93d
24 CH2-Ph (N1) 3.3 ± 0.6
e >99,e 35 ± 9.0
25 CH2-Ph (N2) 7 ± 2.8
e 57 ± 15.6 (4)
26 CH2CH2-2-imidazole (N1) 148 ± 120 −2 ± 1.9 (3)
27 CH2CH2-2-imidazole (N2) 14 ± 1.6 8 ± 26.9 (4)
28 2-py (N1) 32 ± 8.2 −11 ± 13.8 (4)
29 CH2-2-py (N2) >10 000 25 ± 9.4 (4)
30 CH2CH2-2-thiophene (N2) 0.6 ± 0.05 36 ± 5.4 (4)
31 CH2-4-(5-CH3)- Isoxazole (N1) 15 ± 5.4 19 ± 8.6 (4)
32 CH2-C6H4-N-pyrazole (N1) 6.2 ± 3.8 26 ± 9.0 (4)
33 CH2-3,4-benzodioxole (N1) 2.1 ± 0.3 44 ± 2.8 (4)
aValues reported in literature.39 bTested at 30 μM. Results are normalized to the eﬀect of TTX and are based on the mean of at least three
experiments. cTTX tested at 1 μM. dTested at 3 μM. eReported previously39 (values in bold are IC50’s in micromolar).
Table 3. Sodium Channel Modulatory and Neuroprotective Activity of Benzamide-Functionalized Oxadiazolylindazole
Analogues
compound R (isomer) [3H]sipatrigine binding, IC50 (μM) neuroprotection at 50 μM (%)
lamotrigine 1.8 ± 0.2a 33b
tetrodotoxin 100c
sipatrigine 0.04 ± 0.001a 93d
6 CH2CH2-N-imidazole (N1) 13 ± 9 47 ± 15.1 (4)
34e CH2CH2-N-imidazole (N2) 4.5 ± 0.3 19 ± 1.2
41 ± 9.4 (4)
35 CH2-2-py (N2) 41 ± 7 58 ± 4.6 (4)
36 CH2CH2-2-thiophene (N2) >1000 −2 ± 6.2 (4)
37 CH2-4-(5-CH3)-isoxazole (N1) >2000 19 ± 20.0 (4)
aValues reported in literature.39 bTested at 30 μM. Results are normalized to the eﬀect of TTX and are based on the mean of at least four
experiments. cTTX tested at 1 μM. dTested at 3 μM. Values in bold are IC50’s in micromolar.
eTested as a mixture of 83% N1 and 17% N2 isomers.
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ethylthiophene 30, methylisoxazole 31, and substituted benzyls
32 and 33 all showed good binding and modest neuro-
protection.
These results supported the idea that the activity observed
for the indazoles substituted by basic heterocycles at the N1
position was not following a similar SAR pattern to the original
series and required a lipophilic group at the oxadiazolylmethyl-
amine. When the free amine analogues were functionalized with
a benzamide group at the amine moiety, the neuroprotection
and the radioligand-displacement ability of some of the
analogues was improved, with moderate to good levels of
binding observed for N1 and N2 imidazole analogues 6 and 34
(Table 3). Thus, it appeared that a benzamide group could
mimic the action of the tert-butyl carbamate. Methylpyridyl
analogue 35 showed modest binding, whereas ethylthiophene
36 and methyloxazole 37 were essentially inactive.
On the basis of these encouraging eﬀects, a new set of N1 and
N2 imidazole analogues was designed and synthesized to see if
improved binding and neuroprotective activity was achievable.
The new set of N1 and N2 ethyl-2-imidazoles (compounds 38−
64, Table 4) showed a range of activity, with most showing
good ability to displace the radioligand [3H]sipatrigine, and a
range of neuroprotective activity, many with moderate to good
neuroprotection. In the N1-substituted series, all but one of the
11 new analogues had a binding IC50 < 13 μM, with some
compounds having values as low as 1 μM. Similarly, in the N2-
Table 4. Sodium Channel Modulatory and Neuroprotective Activity of N1- and N2-Propylimidazole-Functionalized
Oxadiazolylindazole Analogues
compound N1/N2 functionalized R [
3H]sipatrigine binding, IC50 (μM) neuroprotection at 50 μM (%) or EC50 (bold)
lamotrigine 1.8 ± 0.2a 33b
tetrodotoxin 100c
sipatrigine 0.04 ± 0.001a 93d
38 N1 CO-2,3,4-(OCH3)3Ph 5.3 ± 2.8 37 ± 6.4 (4)
39 N1 CO-4-indole 13 ± 2.0 52 ± 9.9 (4)
40 N1 CO-4-t-BuPh 1.2 ± 0.2 40 ± 34.2 (4)
41 N1 CO-2,3-(OCH3)2Ph 7.1 ± 0.8 69 ± 7.5 (4)
42 N1 CO-3-OCF3Ph 1.5 ± 0.3 37 ± 13.0 (4)
43 N2 CO-4-ClPh 2.2 ± 0.5 42 ± 3.1 (4)
44 N2 CO-2,3-F2Ph 3.6 ± 0.2 2 ± 1.4 (4)
45 N2 CO-4-OCF3Ph 0.7 ± 0.1 31 ± 8.2 (4)
46 N2 CO-2-CH3Ph 2.9 ± 0.5 62 ± 4.4 (4)
47 N2 CO-4-OCH3Ph 6.2 ± 0.7 55 ± 10.7 (4)
48 N2 CO-4-(NHCOCH3)Ph 59 ± 31 −14 ± 3.6 (4)
49 N2 CO-2-naphthalene 0.4 ± 0.2 22 ± 4.4 (4)
50 N2 CO-2,3-(OCH3)2Ph 5.8 ± 1.8 12.3 ± 5.8
88 ± 7.7 (4)
51 N2 CO-3-OCF3Ph 0.6 ± 0.1 5.15 ± 0.15
78 ± 4.2 (4)
52 N2 CO-(3-CH3-4-NO2)Ph 1.7 ± 0.2 43 ± 3.1 (4)
53 N2 CO-3,4-benzodioxole 5.0 ± 0.4 27 ± 4.5 (3)
54 N2 CO-3-CH3Ph 2.5 ± 0.2 41 ± 6.9 (3)
55 N2 CO-2-OCH3Ph 7.1 ± 1.2 54 ± 11.3 (4)
56 N2 CO-3-OCH3Ph 5.0 ± 1.1 63 ± 7.6 (4)
57 N1 SO2-4-ClPh 10 ± 7.1 21 ± 7.9 (4)
58 N1 SO2-2,3-(OCH3)2Ph >500 37 ± 2.5 (4)
59 N1 SO2-4-OCF3Ph 4.9 ± 6.0 0 ± 9.9 (4)
60 N1 SO2-2-CH3Ph 4.9 ± 1.3 57 ± 10.8 (4)
61 N1 SO2-3-CF3Ph 2.1 ± 0.6 38 ± 12.3 (4)
62 N1 SO2-4-t-BuPh 4.4 ± 1.3 16 ± 20.2 (4)
63 N2 SO2-Ph 1.7 ± 0.5 29.5 ± 3.8
38 ± 14 (4)
64 N2 SO2-4-(NHCOCH3)Ph 17 ± 6.8 25 ± 15 (4)
aValues reported in literature.39 bTested at 30 μM. Results are normalized to the eﬀect of TTX and are based on the mean of at least three
experiments. cTTX tested at 1 μM. dTested at 3 μM (values in bold are IC50’s in micromolar).
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substituted series, all but one of the 16 new analogues had a
binding IC50 < 17 μM, with some as low as 0.4 μM.
Neuroprotection eﬃcacy also showed a general increase, with
compound 50 reaching 88% neuroprotection. In the N1 series,
the most profound eﬀect was the 2,3-dimethoxy substitution of
the benzamide ring, 41, which led to a marked increase in
displacement ability (IC50 13 to 7.1 μM) and neuroprotection
(46 to 71%). Interestingly, the analogous trisubstitution at the
2,3,4-positions, 38, resulted in a decrease in neuroprotection.
These aside, in the N1 series, functionalization the benzamide
changed little in terms of activity from the parent, 6 (IC50 range
of 1−13 μM and neuroprotection range of 37−52%), with the
potential to add larger groups, such as a indole 39 or t-butyl 40,
without signiﬁcant loss of binding or neuroprotection.
Compared to the N1 series, the N2 benzamide series had a
much greater range of activities, both in binding (0.4−59 μM)
and neuroprotection (2−89%). The 2-, 3-, and 4-methox-
ybenzamides all showed good binding (IC50 < 8 μM) and
neuroprotection (54−63%), with the 2,3-dimethoxy-substituted
benzamide once again showing the best activity with good
binding (IC50 = 5 μM) and excellent neuroprotection (89%,
EC50 = 12.3 ± 5.8). The benzamide substituted at the 3
position with OCF3 showed comparable activity with binding
(IC50 = 0.8 μM) and neuroprotection (80%). The only other
marked eﬀect was an almost total ablation of neuroprotective
eﬀect by ﬂuorination at the 2 and 3 positions, despite showing
an IC50 of 4 μM in the radioligand-displacement assay. Of all of
the sulfonamide compounds in the N1 series, only one
improved on the neuroprotection of parent benzamide 6,
although many showed better binding. The 2- and 3-substituted
sulfonamide showed good binding and modest neuroprotec-
tion, but substitution at the 4 position seemed to provide
compounds with poor neuroprotective ability, if not binding,
such as 57, 59, and 62. In the N2 series, the sulfonamide
analogue of 34, 63, showed comparable binding and neuro-
protection, but once again, a 4-substituted sulfonamide, 64, had
poorer binding and reduced neuroprotection. In fact, 4-
substituted sulfonamide and benzamide analogues across the
group had reduced capacity for neuroprotection in the
hippocampal slice assay when compared to the 2- or 3-
substituted or unsubstituted compounds, despite no signiﬁcant
diﬀerence in binding. The presence of unfavorable interactions
at the 4 positions is indicated, and this may also account for the
observation that small substituents such as Cl have a lesser
detrimental eﬀect on activity than larger groups. In the limited
number of halide-functionalized benzamides and sulfonamides
tested, none showed improved neuroprotection.
Stability in Rat Liver Microsomes. The N1 and N2 ethyl-2-
imidazole-substituted series was examined for metabolic
stability in rat liver microsomes. Table 5 shows a select subset
of the compounds screened for rate of turnover. When
examined, 14 of 21 compounds tested in this series had
turnovers of greater than 90% after 40 min. Boc-protected and
free amine N2 analogues 17 and 27 showed better metabolic
resistance, with turnovers of 70 and 57 min, respectively.
Functionalization of the amine with benzamide, 34, again
produced an unstable compound. However the N1 analogue, 6,
showed better stability with more than half of the original
compound left after 40 min. Despite this promising result, none
of the further analogues managed to maintain or improve on
this stability, with any substitution making the compounds
signiﬁcantly more labile to metabolic degradation (>90%). Five
benzamide and sulphonamide analogues that were ﬂuorine- or
chlorine-substituted at the 4, 5, and 6 positions on the indazole
ring were also tested to see if this modiﬁcation could arrest the
rate of metabolism. All showed >90% metabolism after 40 min
(data not shown). The only compound with moderately
increased stability was the CO-3-OCF3Ph-substituted benza-
mide, 42. Similarly, substitution of the benzamide or changing
to a sulfonamide did not provide much improvement in the
metabolic stability of the N2 analogues of benzamide 34.
Interestingly, however, substitution at the 4 position with the
amide group, NHCOCH3, in both the sulfonamide 64 and
benzamide 34 analogues gave signiﬁcant improvement in
stability, with turnovers of 54 and 45%, respectively, after 40
min. Unfortunately, these 4 position-substituted NHCOCH3
compounds were also some of the most inactive compounds in
the neuroprotective assay.
Nav Channel Isoform Proﬁling. Compounds 6 and 51 were
examined by patch-clamp electrophysiology to determine their
eﬀects on sodium channel isoforms (Table 6 and Figure 2).
Compound 6 showed preferential activity for the inactivated
state (Figure 2A) but little discrimination between subtypes.
The block of Nav1.1, 1.3, and 1.6 is implicated in the
pharmacological basis of neuroprotection (vide supra), and
activity was noted against these isoforms consistent with the
compounds’ ability to displace radiolabeled sipatrigine (Table
6). Compound 51 showed good activity in both the
radioligand-displacement and neuroprotection assays, and this
is reﬂected in its potent block across the range of isoforms. It
blocks many of the isoforms at an order of magnitude lower
concentration than 6, with its most potent block against the
Nav1.5 sodium channel, an isoform found primarily in cardiac
muscle. There also appears to be less functional selectivity
compared to 6 (Figure 2B). The potency of 51 against Nav1.1,
1.3, and 1.6 when compared to 6 may account for the observed
increase in neuroprotection seen with this compound (Table
6).
In Vivo Activity in an Optic Neuritis Mouse Model of
MS. Compound 6 was selected for detailed in vivo evaluation
on the basis of its mix of properties: in vitro sodium channel
activity, activity against the neuronal Nav isoforms, functional
selectivity, and stability in rat liver microsomes. The inﬂuence
of 6 was assessed in vivo in wild-type and myelin
oligodendrocyte glycoprotein-speciﬁc T-cell receptor transgenic
mice (Figure 4; 5).44 First, 6 was examined for T-cell
immunosuppressive activity, as the EAE model of MS is well-
known to be T-cell-dependent.45 Rather than use transgenic
mice where all T-cells have the same speciﬁcity, a contact-
hypersensitivity model was used because it is known to be
predictive in identifying in vivo immunosuppressive doses for
EAE studies.41−43 Doses of 6 ranging from 5−50 mg/kg were
Table 5. Metabolic Stability Measured in a Rat Liver
Microsome Assay for N1- and N2-Propylimidazole-
Functionalized Oxadiazolylindazole Analogues
compound turnover at 40 min (%)
17 70
27 57
34 97
6 47
42 78
63 97
64 54
48 45
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administered intraperitoneally (i.p.) from day −1 to day 2, and
the in vivo induced proliferative response was assessed in the
draining lymph nodes 3 days (the peak time of T-cell
proliferation) after the sensitization to the contact-sensitizer
oxazolone on day 0. There was no evidence suggestive of any
inhibitory eﬀect of sensitization based on cell numbers within
the lymph nodes or based on a per cell proliferative response
(Figure 3). Importantly, this study demonstrated that the drug
was well-tolerated and there was no apparent toxicity. We next
sought to assess whether 6 could exert a neuroprotective eﬀect
and limit the amount of axonal and nerve loss that results as a
consequence of T-cell autoimmunity within the CNS.
Following the development of optic neuritis in our model
mice, demyelination was augmented following injection of 250
μg of Z12 rat IgG2b demyelinating antibody on day 14.44
Retinal ganglion cell survival following treatment of animals
with 5 mg/kg i.p. 6 was assessed on day 21 postinduction in
retinal ﬂatmounts (Figures 3A,B and 4). It was found that 6
increased ganglion cell survival (P < 0.02) and reduced the
mean retinal loss from 914 ± 117 to 1298 ± 77 cells/mm2
compared to 1653 ± 89 cells/mm2 in a group of age-matched
control animals without optic neuritis (Figure 4). This study
suggests that this class of compounds may have some utility in
controlling the accumulation of nerve loss that occurs in
diseases such as MS.
■ DISCUSSION
During MS, Nav channels are redistributed along demyelinated
nerves, which can help to restore function to some extent but
leaves them vulnerable to excessive sodium entry.18
Our strategy was to develop compounds with good activity
toward sodium channel inhibition, in particular against the
neuronal isoforms Nav1.1, 1.3, and 1.6, but, most importantly,
which could also display neuroprotective capabilities in an in
vitro hippocampal slice assay system. The selection of a
candidate molecule for in vivo studies was based on a balanced
assessment of properties, principally sodium channel activity,
neuroprotection, and in vitro stability. The use of the
hippocampal slice model, measuring ATP levels and tuned
for sodium channel blockade, was key in ensuring an
appropriate functional eﬀect. In general, the series was found
to exhibit poor stability in rat liver microsomes in vitro, with 6
being a notable exception that allowed us to test this paradigm
in vivo. There are reports on the metabolism of 1,2,4-
oxadiazoles,49 and this may be the site of the metabolic
fragility. Studies detailing the pharmacokinetics and localization
of 6 to brain and spinal cord lesions in other EAE models are
published elsewhere.50
Sodium channel blockade with 6 in vivo was found to be
neuroprotective, preventing retinal ganglion cell loss in optic
neuritis in this reﬁned EAE model.44 In this case, the
mechanism of neuroprotection is unlikely to be due to
peripheral immunosuppression that prevents disease from
developing.18,51 There was no evidence of T-cell immunosup-
pression seen here in a paradigm that can detect immunosup-
pressive doses of drugs even following a single dose.
Furthermore, in our hands, overt immunosuppression does
not aﬀect the development of disease in conventional EAE
using a similar delivery of sodium channel-blocking compounds
including phenytoin, sipatrigine, carbamazepine, and oxcarba-
zepine,50 which is in contrast to some studies where
immunosuppression of sodium channel blockers delivered in
the drinking water was noted.18,51 This class of agents has
consistently been found to be neuroprotective.49 Neuro-
protection with 6 is most likely to occur at the level of the
axon or nerve and perhaps through inhibition of microglial
Table 6. Summary of Action of Compounds 6 and 51 on Nav1.1−1.8
tonic block (a) 10 Hz block (b) inactivated-state block (c)
compound IC50 n
a IC50 n IC50 n IC50 b/c
b IC50 a/c
Nav1.1
6 >100 >100 21 ± 6.29 1.71 ± 0.73 >5 >5
51 15.3 ± 5.02 1.09 ± 0.24 8.54 ± 0.72 1.32 ± 0.16 2.55 ± 0.22 2.09 ± 0.32 3.3 6
Nav1.2
6 71 ± 25 1.12 ± 0.51 46 ± 7.42 1.82 ± 0.73 29 ± 1.49 1.48 ± 0.38 1.6 2.4
51 65 ± 22 0.48 ± 0.14 24.1 ± 3.87 0.63 ± 0.14 3.54 ± 1.24 0.6 ± 0.12 6.8 18
Nav1.3
6 >100 >100 22 ± 4.09 0.78 ± 0.15 >5 >5
51 >100 97 ± 72 0.35 ± 0.19 4.76 ± 0.92 0.96 ± 0.19 20 >25
Nav1.4
6 >100 56 ± 16.4 1.21 ± 0.36 24 ± 2.98 1.43 ± 0.27 2.3 >5
51 18.3 ± 1.65 1.23 ± 0.18 10.5 ± 0.47 1.34 ± 0.13 4.58 ± 0.25 1.75 ± 0.12 2.3 4
Nav1.5
6 >100 69 ± 31 1.16 ± 0.54 19 ± 3.06 0.99 ± 0.22 3.6 >5
51 36 ± 19 0.76 ± 0.23 14.8 ± 7.52 0.37 ± 0.13 0.92 ± 0.89 0.49 ± 0.15 16 39
Nav1.6
6 >100 >100 24 ± 7.3 2.45 ± 2.59 >5 >5
51 >100 32.2 ± 25.9 0.42 ± 0.19 3.32 ± 0.53 1.17 ± 0.18 9.7 >30
Nav1.7
6 37 ± 7.0 2.09 ± 1.73 28 ± 1.8 1.88 ± 0.53 14.5 ± 0.73 2.24 ± 0.17 1.9 2.6
51 5.64 ± 0.57 2.59 ± 0.41 4.82 ± 0.33 2.63 ± 0.33 3.02 ± 0.36 2.5 ± 0.1 1.6 1.9
Nav1.8
6 >100 >100 28 ± 0.97 1.42 ± 0.1 >4 >4
51 6.34 ± 1.08 2.14 ± 0.51 5.66 ± 1.47 2.62 ± 1.05 3.77 ± 0.49 2.75 ± 0.66 1.5 1.7
an = the slope of the ﬁt. bThe ratio of IC50 a/c and b/c illustrates the degree of functional selectivity for the inactivated state.
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activity, which are probably central to the pathogenesis of
progressive MS.45,46
Furthermore, some microglial responses are mediated via
Nav channel activity. Therefore, blockade of sodium channels
could result in neuroprotective eﬀects on immune and
nonimmune components that may drive progressive nerve
loss in MS.45,46 Neurodegeneration accumulates slowly over
time and therefore allows a larger time window for treatment
onset compared to acute conditions such as stroke. Lesions in
MS can develop throughout the neuroaxis but are common
within the optic nerve, where optic neuritis is often an initial
sign of disease. The visual pathway is the most accessible part of
the human nervous system, and optic neuritis in MS is
considered to be an ideal tissue to study the eﬀect of
neuroprotective treatments in MS and is being targeted in a
number of studies.47,48 Amiloride and phenytoin are currently
in phase II clinical trials for the treatment of optic neuritis in
MS (NCT01802489, NCT01451593).48 We chose to utilize an
optic neuritis model for in vivo evaluation of neuroprotection in
this study.
Recently, lamotrigine was examined in progressive MS, but it
did not appear to inhibit the development of brain atrophy,
which was the primary outcome measure, although signiﬁcant
eﬀects of slowing of walking deterioration were noted.27 There
is a clear need to evaluate better tolerated and more eﬀective
neuroprotective agents. The chemical series described here may
Figure 2. Detail of activity of 6 (A) and 51 (B) against the Nav1.6
isoform. Blue triangles are block of the inactivated state, red circles are
block of 10 Hz current, and black squares are block of tonic current.
Figure 3. T-cell immunosuppressive activity of 6 in vivo. Mice received
epicutaneous application of 25 μL of 2.5% oxazolone (OX) in acetone
olive oil (AOO) 4:1 on day 0 on the dorsum of the ear. Animals
received daily intraperitoneal (i.p.) injections of either vehicle
(DMSO/Cremophor/phosphate buﬀered saline, 1:1:18) or 6 from
day −1 to day 2. On day 3, the draining auricular lymph nodes were
removed from three mice and pooled, and a single-cell suspension was
made. Lymph node cells were counted, and 5 × 105 cells per well, in
triplicate, were cultured overnight at 37 °C. T-cell proliferation was
assessed using the CellTiter 96 AQueous Cell Proliferation Assay, which
uses a MTS tetrazolium compound that is bioreduced by live cells.
The resulting formazan product absorbance is recorded at 490 nM.
The results represent the mean response ± SD of triplicate assays.
Figure 4. Retinal ganglion cells in the retina of mice (A) before or (B)
after the development of optic neuritis. (C) Density of RGC. The box
represents the 25th and 75th percentiles. The whiskers represent the
ﬁfth and 95th percentiles. The solid line represents the median.
Diﬀerences between vehicle and drug-treated controls were assessed
using Student’s t test.
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provide a platform for the development of pharmaceutical
agents for the treatment of MS and other neurological diseases.
■ EXPERIMENTAL SECTION
All compounds were at least 95% pure as assayed by LCMS
(electrospray positive). The preparations of analogues 6 and 51 are
shown below, and the preparation of the remainder of the analogues is
provided in the Supporting Information.
General Procedure for the Synthesis of Benzamide
Analogues. To a solution of R-substituted benzoic acid (0.10 g,
0.82 mmol) in DMF (5 mL) were added HATU (0.34 g, 0.9 mmol,
1.1 equiv) and diisopropylethylamine (0.23 g, 0.31 mL, 1.8 mmol, 2.2
equiv), and the solution allowed to stir for half of an hour at room
temperature under nitrogen. The amine (0.9 mmol, 1.1 equiv) was
then added, and the brown solution was allowed to stir overnight. The
DMF was removed in vacuo, and the resulting crude oil was dissolved
in ethyl acetate and washed with water, 1 N HCl, 1 N NaHCO3, and
brine. The organic phase was then dried over magnesium sulfate, and
the solvent was removed in vacuo. The crude oil was puriﬁed using
ﬂash chromatography, eluting with 10% methanol in dichloromethane.
General Procedure for the Synthesis of Sulfonamide N1
Analogues. To a solution of the appropriate amine (0.22 g, 0.71
mmol, 1 equiv) in water (10 mL) was added R-substituted benzene
sulfonyl chloride (0.78 mmol, 1.1 equiv). The solution was allowed to
stir, and saturated sodium carbonate(aq) was added gradually to adjust
the acidic pH to 8. The solution was then allowed to stir overnight at
room temperature. The white precipitate was ﬁltered oﬀ, washed with
diethyl ether, and dried in vacuo.
N-[[5-[1-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-
3-yl]methyl]benzamide (6). Orange crystals (18% yield, 98%
purity). 1H NMR (300 MHz, DMSO) δ 9.27 (t, J = 5.7 Hz, 1H,
NH), 8.13 (d, J = 8.1 Hz, 1H, ArH), 7.92 (d, J = 6.7 Hz, 2H, ArH),
7.64 (d, J = 8.5 Hz, 1H, ArH), 7.61−7.41 (m, 4H, ArH), 7.41−7.27
(m, 2H, ArH), 7.02 (s, 1H, ArH), 6.71 (s, 1H, ArH), 4.96 (t, J = 5.8
Hz, 2H, CH2), 4.73 (d, J = 5.7 Hz, 2H, CH2), 4.55 (t, J = 5.8 Hz, 2H,
CH2).
13C NMR (75 MHz, CDCl3) δ 170.1, 168.9, 166.5, 140.8,
137.2, 133.7, 131.5, 129.3, 128.4, 127.7, 127.4, 127.3, 123.7, 121.5,
120.3, 119.6, 110.5, 49.7, 45.7, 35.3. HRMS (TOF MS ES+) calcd for
C22H20N7O2 (MH
+), 414.1678; found, 414.1668.
N-[[5-[2-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-
3-yl]methyl]-2-(triﬂuoromethoxy)benzamide (51). 1H NMR
(300 MHz, CDCl3) δ 8.18 (s, 1H, NH), 8.09 (d, J = 8.4 Hz, 1H,
ArH), 7.99 (d, J = 7.7 Hz, 1H, ArH), 7.95 (s, 1H, ArH), 7.81 (d, J =
8.6 Hz, 1H, ArH), 7.54−7.30 (m, 5H, ArH), 6.69 (s, 1H, ArH), 6.30
(s, 1H, ArH), 5.37 (t, J = 5.5 Hz, 2H, CH2), 4.82 (d, J = 5.1 Hz, 2H,
CH2), 4.55 (t, J = 5.5 Hz, 2H, CH2).
13C NMR (75 MHz, DMSO) δ
237.95, 168.13, 167.26, 164.96, 151.20, 148.34, 147.35, 137.33, 135.81,
130.68, 128.25, 127.08, 126.41, 125.70, 124.15, 122.28, 119.96, 119.79,
119.23, 118.23, 53.29, 45.60, 35.20. HRMS (TOF MS ES+) calcd for
C25H30N10O5 (MH
+), 498.1501; found, 498.1500.
In Vivo. Animals. Six to eight week old male and female wild-type
and double-transgenic C57BL/6-Cg-Tg(Thy1-CFP)23Jrs.Tg
(Tcra2D2,Tcrb2D2)1Kuch/J mice44 were used from stock bred at
Queen Mary University of London. Founder mice were originally
obtained from Jackson Laboratories, Bar Habor, ME, USA). These
transgenic mice express both a H-2Ab-restricted T-cell receptor (Vα3,
Vβ11) speciﬁc for myelin oligodendrocyte glycoprotein residues 35−
55 and a neuronally restricted Thy1 (CD90)-promoter-driven
expression of cyan ﬂuorescent protein, which is only present in the
retinal ganglion cells within the retina.44 Mice were maintained on a 12
h light/dark cycle with controlled humidity and temperature and
housed as described previously.52 The reporting of most aspects of the
experimental design, which conform with the ARRIVE guidelines, has
been described previously.52 Animals were fed RM-1E diet and water
ad libitum. All animal studies were approved by the Queen Mary
ethical review panel and the United Kingdom Government Home
Oﬃce Inspectorate. These studies conformed to the United Kingdom
Animals (Scientiﬁc Procedures) Act 1986 for the use of animals in
research.
In Vivo Local Lymph Node Assay. Mice (n = 3−4/group) received
epicutaneous application of 25 μL of acetone/olive oil (4:1, AOO) or
25 μL of 2.5% oxazolone (OX, Sigma-Aldrich, Poole, UK) on day 0 on
the dorsum of the ear. On day 3, the draining auricular lymph nodes
were removed, and a single-cell suspension was made. Lymph node
cells were counted, and 5 × 105 cells/well, in triplicate, were cultured
overnight at 37 °C/5% CO2 in 200 μL of RPMI-1640 medium
supplemented with 10% heat-inactivated fetal calf serum, L-glutamine,
sodium-pyruvate, and antibiotics as described previously.42 T-cell
proliferation was assessed using the CellTiter 96 AQueous Non-
Radioactive Cell Proliferation Assay according to the manufacturer’s
instructions (Promega, Southhampton, UK). Animals received daily
intraperitoneal (i.p.) injections of either DMSO/Cremophor/
phosphate buﬀered saline (1:1:18) or 6 from day −1 to 2.
Optic Neuritis Multiple Sclerosis Mouse Model. Optic neuritis was
induced in C57BL/6-Cg-Tg(Thy1-CFP)23Jrs.Tg(Tcra2D2,
Tcrb2D2)1Kuch/J transgenic mice. Subclinical EAE in the absence
of paralytic disease was induced following administration of 150 ng of
Bordetella pertussis toxin (Sigma-Aldrich) in phosphate-buﬀered
saline.47 Optic neuritis within the optic nerve was augmented
following the injection of 250 μg of Z12 rat IgG2b mouse myelin
oligodendrocyte-speciﬁc demyelinating antibody on day 14.47 Animals
were injected daily from day 0−21 of the experiment with 5 mg/kg i.p.
Animals were killed on day 21 postinduction, and eyes were
enucleated and immersed in 4% paraformaldehyde (Sigma-Aldrich)
in PBS (pH 7.4) overnight. The retinae were dissected, and the cornea,
sclera, lens, hyaloid vasculature, and connective tissue were removed in
2× normal-strength PBS. Four radial incisions were cut around the
retina, and ﬂatmounts were mounted onto slides and coverslipped with
antifade glycerol (CitiFluor Ltd., London, UK). The retinal ﬂatmounts
were imaged by ﬂuorescent microscopy, retinal ganglion cell density
was calculated by counting cyan ﬂuorescent protein-expressing retinal
ganglion cells using stereology software with a fractionator probe, and
the number cells in the four quadrants around the optic nerve head
was counted.47 The parametric data was assessed using Student’s t test,
incorporating tests for equality of variance using SigmaStat software
(Systat Software, Inc., San Jose, CA, USA).
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[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexa-
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